GlassScriptPhysician profile
Norman Ivan Kier
NPI 1952912131
$2,607.90
in general payments reported to CMS, 2019-2025
22 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.79 · 2022: $29.94 · 2023: $226 · 2024: $61.08 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $473.39 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $471.70 | 2025 | Krystexxa |
| Novo Nordisk INC | $428.38 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.83 | 2025 | Caplyta |
| Agios Pharmaceuticals, INC. | $183.90 | 2025 | Pyrukynd |
| Abbvie INC. | $121.68 | 2023-2025 | |
| Pfizer INC. | $58.70 | 2023-2025 | |
| Sobi, INC | $57.55 | 2021-2022 | |
| Exact Sciences Corporation | $55.41 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $48.49 | 2023 | Spravato |
| Edwards Lifesciences Corporation | $45.60 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Shield Therapeutics INC | $41.63 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $38.07 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.92 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $31.25 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $25.96 | 2025 | Natroba, Spinosad |
| Bayer Healthcare Pharmaceuticals INC. | $22.57 | 2025 | |
| Merck Sharp & Dohme LLC | $20.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.87 | 2025 | Voquezna |
| Qiagen, LLC | $19.19 | 2025 | |
| Glaxosmithkline, LLC. | $15.49 | 2024 | Arexvy, Bexsero, Shingrix |
| Alk-Abello, INC | $13.91 | 2025 | Grastek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Kier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.